Omalizumab Improves Quality of Life (QoL) in Patients with Chronic Spontaneous/Idiopathic Urticaria (CSU/CIU) As Assessed By the Chronic Urticaria Quality of Life Questionnaire (CU-Q2oL): A Post-Hoc Analysis of Percent Change from Baseline to Week 12

被引：0
|
作者：
Janssens, Nico [1 ]
Maurer, Marcus [2 ]
Khalil, Sam [3 ]
Balp, Maria-Magdalena [4 ]
Rosen, Karin [5 ]
机构：
[1] Novartis Pharmaceut, Basel, Switzerland
[2] Charite, Dept Dermatol & Allergy, D-13353 Berlin, Germany
[3] Novartis Pharmaceut, Basel, Switzerland
[4] Novartis Pharma AG, Basel, Switzerland
[5] Genentech Inc, San Francisco, CA 94080 USA
来源：
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY | 2015年 / 135卷 / 02期
关键词：
D O I：
10.1016/j.jaci.2014.12.1363
中图分类号：
R392 [医学免疫学];
学科分类号：
100102 ;
摘要：
424
引用
收藏
页码：AB132 / AB132
页数：1
相关论文
共 24 条
  • [21] Omalizumab improves angioedema-related quality of life impairment in chronic spontaneous urticaria patients: results from the X-ACT study
    Weller, K.
    Staubach, P.
    Metz, M.
    Chapman-Rothe, N.
    Sieder, C.
    Braeutigam, M.
    Maurer, M.
    ALLERGY, 2017, 72 : 96 - 96
  • [22] Omalizumab improves angioedema-related quality of life impairment in chronic spontaneous urticaria patients: Results from the X-ACT study
    Weller, Karsten
    Staubach, Petra
    Metz, Martin
    Chapman-Rothe, Nadine
    Sieder, Christian
    Brautigam, Matthias
    Maurer, Marcus
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2018, 79 (03) : AB209 - AB209
  • [23] Omalizumab reduces Symptoms and improves health related quality of life in Patients with chronic spontaneous Urticaria: A post-hoc-Analysis of Data from three randomised, double blind, placebo-controlled Phase-III-Studies
    Maurer, M.
    Casale, T.
    Saini, S. S.
    Bernstein, J. A.
    Kaplan, A.
    Rosen, K.
    Li, J.
    Georgiou, P.
    Balp, M. M.
    Canvin, J.
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2015, 13 : 120 - 121
  • [24] Improvements In Health-Related Quality Of Life From Asteria I & II: Phase III Studies To Evaluate The Efficacy and Safety Of Omalizumab In Patients With Chronic Idiopathic/Spontaneous Urticaria Who Remain Symptomatic Despite H1 Antihistamine Treatment
    Raimundo, Karina
    Zazzali, James
    Trzaskoma, Benjamin
    Rosen, Karin
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2014, 133 (02) : AB118 - AB118
123